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A B S T R A C  T
background: Many operators are discouraged from performing left main (LM) percutaneous coronary in-
terventions (PCI) in the absence of right coronary artery (RCA) support due to the increased procedure risk. 
Aims: We aimed at assessing the impact of absent functional RCA on prognostic implications in patients 
undergoing unprotected LM PCI.
Methods: 613 patients underwent LM PCI in our department between 2015 and 2019. Consecutive 385 pa-
tients with unprotected LM and at least 1-year follow-up were included in the study. The study 
population comprised 272 patients with unprotected left main coronary artery disease (ULMCAD) with 
dominant RCA, without any significant lesions (Group 1), and 113 ULMCAD patients and without RCA 
support (Group 2).
Results: In Group 2, 32.7% patients had a significant RCA stenosis, 48.7% had chronic total occlusion 
(CTO) of RCA, and 18.6% had recessive RCA. Patients in Group 2 were older and had higher prevalence of 
chronic obstructive pulmonary disease (COPD). SYNTAX Score (median [IQR] 26.0 [20.0–33.0] vs 19.0 
[13.0–25.5]; P <0.001) was higher and left ventricular ejection fraction was lower (median [IQR] 50.0 
[40.0–60.0]% vs 55.0 [45.0–60.0]%; P = 0.01) in this group. All periprocedural complications did not 
differ among the groups. Long-term all-cause mortality at a median follow-up of 1149 days did not 
differ significantly (23% vs 20%; P = 0.37). The long-term mortality in CTO-RCA group was also not 
significantly different.
Conclusions: Patients with ULMCAD who have undergone LM PCI in the absence of RCA support, 
com-pared with those with ULMCAD and RCA support, differed neither in the prevalence of 
periprocedural complications nor in long-term all-cause mortality.
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Significant left main coronary artery (LM) lesions are de-
tected in about 4%–9% of patients referred for coronary 
angiography [1, 2]. Advances in the field of percutaneous 
coronary interventions (PCI) including proper patient 
selection, improvements in device technology, stenting 
techniques, and medical therapy post procedure have all 
made PCI a safe and effective alternative to coronary artery 
bypass graft (CABG) surgery for unprotected LM coronary 
artery disease (ULMCAD) [3–5].
PCI in ULMCAD has shown favorable results in large 
clinical trials and is being widely used worldwide [3, 5–10]. 
However, many operators are discouraged from perform-
ing PCI of the LM in the absence of right coronary artery 
(RCA) support to the left coronary circulation. This is due to 
a potentially increased risk of live-threatening periproce-
dural complications. It is a common belief, that in such 
cases occurrence of significant complications during PCI 
of LM can lead to complete deprivation of blood supply 
to the entire myocardium and may put the patient at an 
unacceptably high risk.
Chronic total occlusion (CTO) of the coronary artery is 
the most common reason for referring patients with LM ste-
nosis requiring revascularization to CABG surgery [11–13] 
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W h A T ’ S  N E W ?
To the best of our knowledge, this is the first study presenting the issue of unprotected left main (Lm) percutaneous coronary 
intervention (PCI) in the absence of functional right coronary artery (RCA) in the broad sense. Absence of RCA support was 
defined as presence of recessive RCA, significant stenosis of RCA or total occlusion of RCA. We found that patients with unpro-
tected Lm coronary artery disease PCI with absent RCA support had the same frequency of periprocedural complications and 
long-term all-cause mortality rate, as patients with unprotected Lm coronary artery disease with RCA support. Therefore, PCI 
of Lm could be a safe and effective procedure, also in patients with absence of RCA support.
which explains a relatively low incidence of CTO-RCA in 
previous randomized LM studies [14]. A similar issue also 
concerns the absence of RCA support, when a significant 
stenosis and/or an anatomically recessive variant of RCA 
is present. The impact of RCA support absence on the 
outcomes of patients undergoing PCI for unprotected LM 
disease continues to be of interest. The aim of the present 
study was to assess whether the absence  of RCA circulation 
carries prognostic implications in patients undergoing 
unprotected LM PCI.
METHOdS
Six hundred and thirteen patients who underwent PCI of 
LM in our department from January 2015 to June 2019 were 
included in the initial analysis. Consecutive 385 patients 
with unprotected LM and with at least 1-year follow-up 
were included in a prospective registry presented in this 
paper. Inclusion criteria were: presence of ≥50% diameter 
stenosis of unprotected LM with or without the involve-
ment of the left anterior descending artery, ostial circumflex 
coronary artery (LCx), or both of the above. In patients 
with moderate lesions, the intravascular ultrasound im-
aging (IVUS) was used to confirm the significance of the 
stenosis, with a cut-off value of a minimal lumen area of 
6.0 mm2. Terminal patients whose expected survival was 
less than one year were excluded from the study. The 
invasive procedures were performed after a Heart Team 
Meeting with a cardiac surgeon, by an experienced invasive 
cardiologists, at a high volume referral center with Cardiac 
Surgery Department on site. 
The study group consisted of 272 patients with ULM-
CAD with dominant RCA, without any significant lesions 
(Group 1), and 113 patients with ULMCAD and without RCA 
support (Group 2). Absence of RCA support was defined 
as the presence of recessive RCA, significant stenosis of 
RCA, or total occlusion of RCA. A coronary artery system 
was classified as right dominant when the posterior de-
scending artery (PDA) originated from the right coronary 
artery, while left dominance was defined as PDA originating 
from the LCx.
The clinical and angiographic data of these patients, 
including short- and long-term outcomes were analyzed. 
Baseline clinical data were collected for each patient 
at the index procedure. The main procedural data with 
all periprocedural and in-hospital complications were 
collected and analyzed. Chronic kidney disease was 
defined as decreased kidney function established on 
the basis of glomerular filtration rate <60 ml/min for 
3 months or more, calculated by the Cockcroft–Gault 
equation. All bifurcation lesions were classified angio-
graphically according to the Medina classification [15]. 
Patients with LM equivalent disease, i.e., distal bifurca-
tion Medina 0–1–1, who presented <70% stenoses of 
the ostial left anterior descending artery or LCx without 
any evidence of ischemia in its myocardial distribution, 
were not included in the study [5]. CTO-RCA was defined 
as complete occlusion of RCA with 0 flow lasting at 
least 3 months, regardless of the occlusion location. In 
patients with coexisting diseases of the LM and the RCA, 
the decision about the sequence of procedures was up 
to the operator’s discretion. In the group with lack of RCA 
support the decision to treat LM prior to RCA was made. 
Patients were treated with the intention to achieve com-
plete revascularization of all their major vessels bearing 
significant lesions; consequently they were scheduled 
for future procedures. The decision regarding CTO-RCA 
treatment was taken after PCI of LM. Therefore, all the 
analyzed patients in the CTO-RCA group at the time of 
analysis exhibited residual CTO. Some patients with LM 
lesions and concomitant RCA disease had RCA PCI prior 
to LM PCI and were not included in the group with lack of 
RCA support. Periprocedural myocardial infarction (type 
4a) was diagnosed based on European Society of Cardiol-
ogy Fourth Universal Definition of Myocardial Infarction 
(2018) [16]. A glycoprotein IIb/IIIa receptor blocker, IVUS, 
and optical coherence tomography (OCT) were used at 
the operator’s discretion. However, IVUS or OCT imaging 
were used in 118 (30.65%) patients and were not analyzed 
in great detail. The antiplatelet regimens were low-dose 
aspirin (75 mg daily) and clopidogrel (75 mg daily) for 
a minimum of 6 months after PCI, with the intention of 
12 months of dual antiplatelet therapy.
The primary short-term outcome of the study was the 
composite of in-hospital death or myocardial infarction. 
Whereas, the long-term study end point was all-cause mor-
tality. The median follow-up was 1149 days (max: 1650 days, 
interquartile range: 541 days). The data were collected by 
telephone or based on the official records of the National 
Health Fund. The registry conforms to the ethical guide-
lines of the 1975 Declaration of Helsinki and was granted 
ethics approval by the Institutional Review Board and the 
Bioethics Committee of the University. 
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Statistical analysis was performed using STATISTICA 
12 (Tibco Software Inc., Palo Alto, CA, USA). A standard de-
scriptive statistics are presented as medians (interquartile 
range, [IQR]). The normality distribution was analyzed using 
the Shapiro-Wilk test. The statistical significance of differ-
ences was tested with the nonparametric U Mann-Whitney 
test. Categorical variables were reported as counts or 
percentages and compared by tests for proportions. The 
Kaplan-Meier method was used to calculate the survival 
probability at follow-up. The survival curves were compared 
with the log-rank test. A two-sided P-value of <0.05 was 
considered significant for all the tests.
RESulTS
From the total cohort of 613 patients who underwent PCI 
of LM in our department, a total number of consecutive 
385 unprotected LM PCI patients, with at least 1-year 
follow-up (median [IQR] age, 68.0 [62.0–76.0] years, 74.3% 
male), were included in this analysis. Patient baseline 
characteristics are presented in Table 1. Patients with ab-
sence of RCA support (Group 2) were older (median [IQR], 
69.0 [64.0–78.0] vs 68.0 [61.0–74.0] years; P = 0.03) and 
had higher prevalence of COPD (15.0% vs 6.3%; P = 0.006). 
The groups did not differ in other cardiovascular risk 
factors. Left ventricular ejection fraction (LVEF) was signif-
icantly lower in Group 2 (median [IQR], 50.0 [40.0–60.0] vs 
55.0 [45.0–60.0]; P = 0.01), with no significant differences in 
other echocardiographic parameters. Euroscore II was con-
sequently higher in Group 2 (median [IQR], 2.01 [1.41–2.89] 
vs 1.20 [0.82–2.34]; P = 0.002). 
Coronary artery disease characteristics are shown 
in Table 2. Of the 113 patients from Group 2, 37 (32.7%) 
had a significant stenosis of RCA, 55 (48.7%) chronic total 
occlusion (CTO) of RCA, and 21 (18.6%) recessive RCA. 
CTO of RCA with collateral circulation from left coronary 
artery (LCA) was described in 40 (35.4%) patients from 
Group 2. Moreover, more patients in the Group with ab-
sent RCA support had severe disease of the LCx (39.8% vs 
27.2%; P = 0.02) and calcifications in LM (20.4% vs 11.4%; 
P = 0.02). SYNTAX Score was significantly higher in Group 
2 (median [IQR], 26.0 [20.0–33.0] vs 19.0 [13.0–25.5]; P 
<0.001) and these patients more often required the use of 
two-stent techniques (29.2% vs 17.3%; P = 0.009). Patients 
in Group 2 had more advanced atherosclerotic disease 








(group 1 vs group 2)
Age, years 68.0 (62.0–76.0) 68.0 (61.0–74.0) 69.0 (64.0–78.0) 0.03
Gender, male 286 (74.3) 198 (72.8) 88 (77.9) 0.30
BMI, kg/m2 27.8 (24.9–30.8) 28.1 (25.1–31.1) 27.2 (24.3–30.2) 0.24
Hypertension 311 (80.8) 218 (80.2) 93 (82.3) 0.63
Hyperlipidemia 190 (49.4) 135 (49.6) 55 (48.7) 0.86
CKD 133 (34.5) 89 (32.7) 44 (38.9) 0.24
DM 139 (36.1) 101 (37.1) 38 (33.6) 0.51
Stroke/TIA 29 (7.5) 21 (7.7) 8 (7.1) 0.83
COPD 34 (8.8) 17 (6.3) 17 (15.0) 0.006
PVD 54 (14.0) 35 (12.9) 19 (16.8) 0.31
AF 48 (12.5) 35 (12.9) 13 (11.5) 0.71
Cigarette smoking (current) 143 (37.1) 98 (36.0) 45 (39.8) 0.48
Prior MI 181 (47) 127 (46.7) 54 (47.8) 0.84
Prior PCI LAD 91 (23.6) 69 (25.4) 22 (19.5) 0.22
Prior PCI LCx 55 (14.3) 36 (13.2) 19 (16.8) 0.36
Prior PCI RCA 116 (30.1) 101 (37.1) 15 (13.3) <0.001
Prior CABG 26 (6.8) 17 (6.3) 9 (8.0) 0.54
Clinical presentation
Stable angina 220 (57.1) 159 (58.5) 61 (54.0) 0.42
Unstable angina 113 (29.4) 80 (29.4) 33 (29.2) 0.97
NSTEMI 37 (9.6) 22 (8.1) 15 (13.3) 0.12
STEMI 11 (2.9) 8 (2.9) 3 (2.7) 0.88
LVEDD, mm 50.0 (47.0-55.0) 50.0 (47.0-55.0) 50.5 (46.0-56.0) 0.65
LVEF, % 55.0 (45.0–60.0) 55.0 (45.0–60.0) 50.0 (40.0–60.0) 0.01
EuroScore II 1.45 (0.88–2.44) 1.20 (0.82–2.34) 2.01 (1.41–2.89) 0.002
SYNTAX Score 21.0 (15.0–28.0) 19.0 (13.0–25.5) 26.0 (20.0–33.0) <0.001
0–22 (low) 210 (54.5) 176 (64.7) 34 (30.1) <0.001
23–32 (intermediate) 117 (30.4) 67 (24.6) 50 (44.2)
≥33 (high) 58 (15.1) 29 (10.7) 29 (25.7)
Data are presented as number (percentage) of patients or median (IQR) unless otherwise indicated.
Abbreviations: AF, atrial fibrillation; BMI, body mass index; CABG, coronary artery bypass graft; CKD, Chronic Kidney Disease; COPD, chronic obstructive pulmonary disease; 
DM, diabetes mellitus; LAD, left anterior descending artery; LCx, left circumflex; LVEDD, left ventricular enddiastolic diameter; LVEF, left ventricular ejection fraction; MI, my-
ocardial infarction; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; RCA, right coronary artery; TIA, transient ischemic attack
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P-value (group 1 vs 
group 2)
LM distal 312 (81.0) 219 (80.5) 93 (82.3) 0.68
LM bifurcation 246 (63.9) 172 (63.2) 74 (65.5) 0.68
LM trifurcation 44 (11.4) 27 (9.9) 17 (15.0) 0.15
LM calcification 54 (14.0) 31 (11.4) 23 (20.4) 0.02
LAD disease (not ostial) 192 (49.9) 129 (47.4) 63 (55.8) 0.14
LCx disease (not ostial) 119 (30.9) 74 (27.2) 45 (39.8) 0.02
Protected LM 0 (0) 0 (0) 0 (0) —
RCA recessive (a) 21 (5.5) 0 (0) 21 (18.6) <0.001
RCA with significant stenosis (b) 37 (9.6) 0 (0) 37 (32.7) <0.001
RCA total occlusion (c) 55 (14.3) 0 (0) 55 (48.7) <0.001
Lack of RCA support (a + b + c) 113 (29.4) 0 (0) 113 (100) <0.001
CTO of RCA with collateral circulation from LCA 40 (10.4) 0 (0) 40 (35.4) <0.001
Extent of diseased vessels
LM plus 2-vessel disease 93 (32.6) 47 (17.3) 46 (40.7) <0.001
LM plus 3-vessel disease 29 (7.5) 0 (0) 29 (25.7) <0.001
Bifurcation medina
1-0-0 85 (22.1) 59 (21.7) 26 (23.0) 0.78
1-0-1 27 (7.0) 22 (8.2) 5 (4.4) 0.20
1-1-0 79 (20.5) 57 (21.0) 22 (19.5) 0.74
1-1-1 55 (14.3) 34 (12.5) 21 (18.6) 0.12
Data are presented as number (percentage) of patients unless otherwise indicated.
Abbreviations: CTO, chronic total occlusion; LAD, left anterior descending artery; LCA, left coronary artery; LCx, left circumflex; LM, left main; RCA, right coronary artery








(group 1 vs group 2)
PCI success 383 (99.5) 271 (99.6) 112 (99.1) 0.89
Number of stents 2.0 (1.0–2.0) 1.0 (1.0–2.0) 2.0 (1.0–2.0) 0.12
Total length of implanted stents, mm 33.0 (23.0–48.0) 32.0 (23.0–47.0) 39.0 (23.0–56.0) 0.07
Radiation time, min 15.0 (11.0–22.0) 14.0 (10.0–21.0) 17.0 (11.0–24.0) 0.02
Radiation dose, mGy 1237 (813–1886) 1237 (826–1838) 1238 (734–2161) 0.34
Contrast volume, ml 220 (180–300) 215 (180–300) 230 (180–300) 0.43
Arterial access site
Radial 238 (61.8) 166 (61.0) 72 (63.7) 0.62
Femoral 147 (38.2) 106 (39.0) 41 (36.3)
Stenting LM only 48 (12.5) 35 (12.9) 13 (11.5) 0.71
Stenting LM bifurcation
One-stent technique 257 (66.8) 190 (69.9) 67 (59.3) 0.045
Two-stents technique 80 (20.8) 47 (17.3) 33 (29.2) 0.009
Two-stents techniques Total, n = 80 n = 47 n = 33
Crush 27 (33.8) 14 (29.8) 13 (39.4) 0.37
DK-Crush 11 (13.8) 7 (14.9) 4 (12.1) 0.98
Cullote 1 (1.3) 1 (2.1) 0 (0) 0.86
T-stenting 17 (21.3) 10 (21.3) 7 (21.2) 0.99
Provisional stenting 24 (30) 15 (31.9) 9 (27.3) 0.67
Periprocedural outcomes
Myocardial infarction 18 (4.7) 14 (5.2) 4 (3.5) 0.50
In-hospital Death 2 (0.5) 2 (0.7) 0 (0) 0.36
Stroke 1 (0.3) 1 (0.4) 0 (0) 0.65
Tamponade 2 (0.5) 0 (0) 2 (1.8) 0.09
Pulmonary oedema 1 (0.3) 0 (0) 1 (0.9) 0.29
Dissection of aorta 1 (0.3) 0 (0) 1 (0.9) 0.29
Perforation of femoral artery 1 (0.3) 1 (0.4) 0 (0) 0.65
Contrast induced nephropathy 16 (4.2) 11 (4.0) 5 (4.4) 0.91
Data are presented as number (percentage) of patients or median (IQR) unless otherwise indicated.
Abbreviations: DK-Crush, double kissing crush technique; LM, left main; PCI, percutaneous coronary intervention
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Figure 1. A. Kaplan-Meier analysis of all-cause mortality: Group 1 (patients with dominant RCA and without any significant lesions) vs Group 
2 (patients with ULMCAD and absence of RCA support). b. Kaplan-Meier analysis of all-cause mortality: patients with RCA support vs patients 
with CTO of RCA. Abbreviations: see Table 1
and procedure radiation time was higher (median [IQR], 
17.0 [11.0–24.0] min vs 14.0 [10.0–21.0] min; P = 0.02). 
Various stenting techniques were used. No significant 
differences in the frequency of use of selected stenting 
techniques were observed (Table 3). All LM lesions were 
stented with second-generation drug-eluting stents (DES). 
Number of stents and total length of implanted stents did 
not differ significantly between the two groups. Artery 
access was similar and it was more often radial approach 
in both groups. An early success rate was very high (99%) 
and did not differ between the groups. All LM procedures 
were carried out without left ventricular assist devices.
Periprocedural clinical outcomes are summarized at the 
end of Table 3. Frequency of all the perioperative compli-
cations (9.7% vs 8.1%; P = 0.60) was similar in both study 
groups. Periprocedural mortality and myocardial infarction 
(type 4a) did not differ between the groups. Long-term 
all-cause mortality did not differ significantly (23% vs 20%; 
P = 0.37) between the two study groups either (Figure 1A).
In subanalysis, long-term mortality in patients with CTO 
of RCA was not  different compared to the patients without 
absent RCA support (22% vs 20%; P = 0.75) (Figure 1B). The 
incidence of perioperative complications in the group of 
patients with CTO-RCA, compared to the patients without 
absence of RCA support, was also not  different (9.09% vs 
8.09%; P = 0.82).
dISCuSSION
The main conclusion of the study is the fact that absence 
of RCA support during PCI of LM was not associated with 
an increased number of periprocedural complications and 
in-hospital mortality, and in the presence of such circum-
stances the procedure is still deemed safe. However, it 
should be highlighted that there exists a risk of complica-
tions and such complex procedures, especially in absence 
of RCA support, should be performed in high-volume 
reference centers with quick access to cardiac surgery and 
the eventual use of left ventricular assist devices [17, 18].
Several papers have been published showing long-term 
outcomes of PCI of LM in presence of CTO-RCA [19–21], 
however, they were restricted only to the patients with 
CTO. The papers did not deal with the lack of RCA support 
in a situation of recessive or significantly stenotic RCA. To 
the best of our knowledge, the present study is the first 
one which raises the issue of unprotected LM PCI in the 
absence of functional RCA in the broad sense.
The analysis of population from the EXCEL study shows 
that among 1753 patients included in the study, an oc-
cluded RCA at baseline was present in 130 patients (7.4%) 
[19], which was analogous to our analysis, where CTO-RCA 
was noted in 14.3% of the patients. In EXCEL, the patients 
with an occluded RCA more frequently had a peripheral 
vascular disease, prior PCI, lower LVEF, and a significantly 
higher SYNTAX Score [19]. However, the frequency of 
comorbidities in our real-life study was much higher than 
in the groups from the randomized EXCEL trial, where di-
abetes and renal insufficiency occurred in 33.6% vs 27.7% 
and 38.9% vs 14.4% respectively. It must be pointed out 
that frequency of periprocedural myocardial infarction was 
similar in both groups. Also, the success of LM angioplasty 
did not differ in both groups, despite an increased difficulty 
of the procedures in patients in Group 2.
Absence of RCA support (similarly to CTO-RCA) had 
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real-world cohort study are in line with the results ob-
tained in the EXCEL trial, where the presence of occluded 
RCA was also not independently associated with a higher 
30-day, or a 3-year MACCE risk (a composite of death 
from any cause, e.g. stroke or myocardial infarction) [19]. 
These results are, however, contrary to these presented 
by other authors. In the prospective registry (involving 
78 patients with CTO-RCA and ULMCAD) that assessed the 
impact of CTO-RCA in patients undergoing unprotected 
LM PCI, Migliorini et al. [20] showed that the CTO-RCA is 
a significant predictor of mortality in patients with UL-
MCAD undergoing PCI. This major difference may result 
from older age (71 years vs 69 years) and more likely from 
lower LVEF (39.0% vs 45%) in the study by Migliorini et al. 
[20]. Similar findings to those by Migliorini et al. [20] were 
presented by Takagi et al. [21]. In their study (75 patients 
with CTO-RCA), cardiac death occurred more frequently 
in patients with residual CTO-RCA, as compared to those 
without residual CTO-RCA. Takagi et al. [21] also showed 
that recanalization of CTO-RCA had a significant impact on 
long-term cardiac-mortality in patients undergoing ULM-
CAD PCI, probably due to retrograde coronary circulation 
in these patients, in the event of LM stent restenosis. It 
is noteworthy that 5-year all-cause mortality in patients 
with residual CTO in the study by Takagi et al. [21]  was 
relatively high, reaching up to 31% — this result, however, 
may be the consequence of a large proportion of patients 
with chronic kidney disease (60.9%) in this group and the 
use of first generation DES.
Our study focuses not only on CTO-RCA, which in an 
obvious way increases SYNTAX Score and correlates with 
a more severe clinical condition, but unlike other studies, 
it also deals with the issues of the absence ofthe RCA sup-
port and  performing high-risk procedures in the presence 
of only functional left coronary artery. In some cases, the 
presence of significant stenosis in RCA only slightly affects 
the SYNTAX Score, but in real-life practice it significantly 
increases the risk of the procedure. Interestingly, in Group 
2 in our study, significantly more frequent use of two-stent 
techniques was observed, which probably results from 
advanced atherosclerotic disease in all coronary arteries 
and higher percentage of LM plus 2- and 3-vessel disease. 
Higher incidence of diffuse coronary atherosclerosis may 
result in an incomplete revascularization PCI, and a large 
survey study in the DES era revealed that incomplete re-
vascularization associated with CTO carries a worse prog-
nosis and a higher risk of death, compared with complete 
revascularization [22]. In our study, we treated patients with 
the intention of achieving total revascularization, however, 
the decision to treat CTO-RCA, as well as severe stenosis 
of RCA, was undertaken after LM PCI and was performed 
at a later stage.
In summary, the most important conclusion of our 
study is that angioplasty in patients in the absence of RCA 
support is a safe procedure that does not significantly in-
crease the incidence of complications. Our study includes 
real-life patients and proves that the absence of RCA sup-
port or CTO-RCA does not necessarily significantly increase 
long-term mortality.
Study limitations
The presented study is an analysis of a real-world cohort 
of patients. One limitation of the study involves the lack of 
a surgical group. However, the comparison of such a group 
with the CABG group was beyond the scope of this study. 
Secondly, although the presented study was a prospective 
registry, not all clinical data were available. Thirdly, the 
analyzed population was a population of patients treated 
in a real-word setting, therefore, many patients with ULM-
CAD had multivessel disease and PCI was not just about 
LM, which can influence the prognosis. Finally, the present 
study analyzed in-hospital, as well as long-term follow-up 
with the median observation time of over 3 years. However, 
the long-term follow-up assessed all-cause mortality and 
we were not able to show cardiovascular vs non-cardiovas-
cular death rates analysis.
CONCluSIONS
Patients with ULMCAD who have undergone LM PCI 
with absent RCA support, compared with patients with 
ULMCAD with RCA support, differed neither in the fre-
quency of periprocedural complications nor in long-term 
all-cause mortality.
These findings suggest that PCI of LM could be a safe 
and effective procedure, also in patients without RCA sup-
port.
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